Expert Interview
Discussing Novo Nordisk's Semaglutide prior to the topline data readout of the ongoing Phase 3 evoke and evoke+ trials for early-stage Alzheimer’s disease
Ticker(s): NVOInstitution: University of Kansas
- Director of NIH-funded University of Kansas Alzheimer's Disease Center.
- Currently manages 300 patients with Alzheimer's disease.
- Research is focused on brain energy metabolism, the role brain energy metabolism plays in Alzheimer's Disease, and how to manipulate brain energy metabolism.
How important are the biomarker components of these trials, such as neuroinflammatory markers, amyloid/tau measures, and CSF analyses, in interpreting whether semaglutide is having a disease-modifying effect?
If semaglutide ultimately shows a significant benefit, how do you envision it fitting into the current AD treatment landscape alongside monoclonal antibodies like lecanemab and donanemab?
Added By: sara_adminAre there specific safety or tolerability considerations unique to older adults with early AD that you believe will influence clinical uptake if semaglutide becomes an approved therapy?
Added By: sara_adminFrom a trial-design perspective, what stands out to you about evoke/evoke+ (e.g., long treatment duration, oral formulation, amyloid-confirmed population), and what factors will most strongly determine whether the results are clinically meaningful?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
